Drug intelligence / Profile preview

Aleozen

Development stage: Phase 1
Lead developer: Aleonat
Administration: Oral

Overview

**Aleozen** is an orally administered Tunisian herbal dietary supplement manufactured by Aleonat. It is a proprietary botanical mixture containing extracts of griffonia, rhodiola, gentian, hawthorn, California poppy, and lemon balm, marketed for stress, insomnia, anxiety, and mild to moderate depression. Aleozen was evaluated against placebo as an early intervention to prevent post-traumatic stress disorder in the PHYTéS randomized clinical study; its molecular targets and a validated single mechanism of action have not been established.

Brand names: AleozenAleozen Gélules

Beyond the preview

Go deeper on Aleozen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aleozen.

Explore the full profile